Advertisement

Advertisement

Gynecologic Cancers

Hormonal Therapy and Risk of Ovarian Cancer

Ovarian cancer is the second most common gynecologic malignancy in the United States, with an estimated 21,290 new cases expected this year. Ovarian cancer causes 5% of all cancer deaths in women, making it responsible for the highest number of gynecologic cancer deaths.1 Age, family history, and...

Gynecologic Cancers

Meta-analysis Shows Increased Risk of Ovarian Cancer With Menopausal Hormone Therapy

In a study reported in The Lancet, the Collaborative Group on Epidemiological Studies of Ovarian Cancer found that use of menopausal hormone therapy was associated with increased risk of ovarian cancer, with risk being highest among current users.1 The study consisted of meta-analyses of...

Gynecologic Cancers
Geriatric Oncology

Gynecologic Cancer in the Older Patient: The Activities of the Elderly Working Group of NRG Oncology

Geriatrics for the Oncologist is guest edited by Stuart Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Visit SIOG.org for more on geriatric oncology.   The elderly population in the United States is growing, and by the year...

Bladder Cancer
Prostate Cancer
Gynecologic Cancers

Clinical Trials Actively Recruiting Patients With Genitourinary Cancers

The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with genitourinary cancers—prostate, bladder, uterine, and testicular. The trials are investigating genetic biomarkers of cancer; proton beam therapy; allogeneic bone marrow...

Gynecologic Cancers

How Carolyn D. Runowicz, MD, FASCO, Is Shaping the Future of Gynecologic Cancers

Carolyn D. Runowicz, MD, ­FASCO, has worn just about every hat in the field of oncology—clinician, professor, researcher, administrator, and even cancer survivor.  Currently the Executive Associate Dean for Academic Affairs and Professor in the Department of Obstetrics and Gynecology at the Herbert ...

Gynecologic Cancers

Bevacizumab in Ovarian Cancer: Results of ICON7

Based on preclinical (in vitro and in vivo) data, there is a strong biologic rationale for the addition of an antiangiogenic drug strategy in the treatment of epithelial ovarian cancer.1 Single-agent trials have confirmed both the biologic and clinical activity of bevacizumab (Avastin) in the...

Gynecologic Cancers

Addition of Bevacizumab to Standard Chemotherapy Improves Overall Survival Only in High-Risk Ovarian Cancer

Final overall survival results of the phase III ICON7 trial reported in The Lancet Oncology by Amit M. Oza, MD, and colleagues indicate no significant improvement with the addition of bevacizumab (Avastin) to standard chemotherapy in women with newly diagnosed ovarian cancer.1 However, an overall...

Gynecologic Cancers

ASCO-Endorsed ASTRO Guidelines: Searching for Consensus on Radiotherapy for Endometrial Cancer

Endometrial cancer is the most common gynecologic cancer, but there has been little consensus about the appropriate indications for adjuvant therapy. One reason for the lack of consensus is the absence of randomized studies in endometrial cancer that report an overall survival benefit. This may be...

Gynecologic Cancers

ASCO Endorses ASTRO Guideline on Postoperative Radiation Therapy for Endometrial Cancer

As reported in the Journal of Clinical Oncology by Larissa A. Meyer, MD, MPH, and colleagues, ASCO has endorsed the recently published American Society for Radiation Oncology (ASTRO) guideline on postoperative radiation therapy for endometrial cancer.1 The ASCO clinical practice guideline...

Gynecologic Cancers

Ovarian Cancer Trialists Forming Work Group to Standardize Definition of Pathologic Complete Response

Ovarian cancer clinical trialists are forming a working group to develop a standard definition of pathologic complete response in ovarian cancer treated with neoadjuvant chemotherapy. Such agreement within the field potentially would enable the U.S. Food and Drug Administration (FDA) to consider...

Gynecologic Cancers

Ovarian Cancer: Current Treatment and Patient Management

Tough initial treatment decisions have “long-lasting ramifications and affect the entire treatment paradigm” for women with ovarian cancer, according to Bradley J. Monk, MD, FACS, FACOG, of the University of Arizona Cancer Center, Phoenix. In a true collaborative presentation at the Annual JADPRO...

Gynecologic Cancers

Women Coinfected With Human Papillomavirus Had Reduced Risk for Invasive Cervical Cancer

Women co-infected with low-risk and high-risk human papillomavirus (HPV) had a reduced risk for invasive squamous cervical carcinoma and a longer time to progression than did women infected with high-risk human papillomavirus alone, according to a Swedish study published in the Journal of the...

Gynecologic Cancers
Issues in Oncology

A Shot to End Cancer: HPV Vaccination

As health-care providers, we have an obligation and a responsibility not only to care for our patients, but also to educate them—and the general public—about their cancer risk and ways to reduce or prevent it. We are living in the golden era of cancer prevention and treatment, made possible by...

Advertisement

Advertisement

Advertisement